The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the compan
Shares in Argenx have been taking a bashing this morning after the company announced its new subcutaneous formulation of Vyvgart had missed the mark in another phase 3 tri
Argenx has been riding high of late thanks to buoyant sales growth for its Vyvgart therapy for muscle-wasting disease generalised myasthenia gravis (gMG), but a failed pha
The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u
The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.